Page last updated: 2024-11-02

pirenzepine and Psychomotor Agitation

pirenzepine has been researched along with Psychomotor Agitation in 22 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.

Research Excerpts

ExcerptRelevanceReference
"This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia."9.10Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."9.10A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."9.09Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine."9.09Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001)
" This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment."7.71Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."6.70Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
" In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2."5.10Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003)
"This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia."5.10Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."5.10A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
" This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline."5.09The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."5.09Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine."5.09Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001)
" ziprasidone and olanzapine for treating acute agitation in patients with schizophrenia are described, along with factors to consider when evaluating the cost-effectiveness of these agents."4.81Continuum of care: stabilizing the acutely agitated patient. ( Bellnier, TJ, 2002)
" This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment."3.71Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001)
" A new approach to olanzapine dosing that expands the initial dose range up to 40 mg/d may offer superior efficacy in rapidly and effectively controlling the symptoms of agitation."2.71Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. ( Baker, RW; Hill, AL; Kinon, BJ; Liu, H; Maguire, GA, 2003)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."2.70Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
" These findings suggest that intramuscular olanzapine is a safe and effective treatment for reducing acute agitation in patients with bipolar mania."2.70A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. ( Breier, A; David, S; Janicak, P; Koch, M; Meehan, K; Rizk, R; Small, J; Tohen, M; Tran, P; Walker, D; Zhang, F, 2001)
" Risk factors are a high dosage of antipsychotics, akathisia in a previous treatment, and diabetes mellitus."2.41[Drug-induced akathisia]. ( van Harten, PN, 2002)
"Olanzapine proved to be an adequate treatment choice for NIA patients."1.30Measuring neuroleptic-induced akathisia by three-channel actometry. ( Holi, M; Lauerma, H; Markkula, J; Rimon, R; Tuisku, K, 1999)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (9.09)18.2507
2000's20 (90.91)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellnier, TJ1
Olson, DA1
Ingram, W1
Mann, JR1
Hall, KL1
Taylor, WH1
Ware, MR1
Daniel, DG1
Battaglia, J1
Lindborg, SR1
Alaka, K1
Meehan, K5
Wright, P3
Baker, RW1
Kinon, BJ2
Maguire, GA1
Liu, H1
Hill, AL2
Landi, F1
Cesari, M1
ZuccalĂ , C1
Barillaro, C1
Cocchi, A1
Buckley, PF1
Tuisku, K1
Lauerma, H1
Holi, M1
Markkula, J1
Rimon, R1
Feifel, D1
Roychowdhury, SM1
Milton, DR1
Jones, B2
Taylor, CC2
Clark, WS1
Street, JS1
Feldman, PD2
Breier, A5
Birkett, M2
David, SR2
Ferchland, I2
Alaka, KJ1
Saunders, JC1
Krueger, J1
Bradley, P1
San, L1
Bernardo, M1
Reinstein, M1
Ishigooka, J1
Murasaki, M1
Miura, S1
Zhang, F1
David, S2
Tohen, M1
Janicak, P1
Small, J1
Koch, M1
Rizk, R1
Walker, D1
Tran, P1
Schneider, LS1
Tariot, PN1
Lyketsos, CG1
Dagerman, KS1
Davis, KL1
Davis, S1
Hsiao, JK1
Jeste, DV1
Katz, IR1
Olin, JT1
Pollock, BG1
Rabins, PV1
Rosenheck, RA1
Small, GW1
Lebowitz, B1
Lieberman, JA1
Cassidy, EM1
O'Brien, M1
Osman, MF1
Finucane, J1
O'Keane, V1
van Harten, PN1
Meehan, KM1
Wang, H1
Nisivoccia, JR1
Beasley, CM1
Mintzer, JE1
Beckett, LM1
Sutton, V1
Palmer, R1
Dossenbach, M1
Kiesler, G1
Brook, S1
Sheikh, RM1
Ahmed, K1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Individualized Music Playlist Based on ISO-Principle for De-escalating Agitation of People Living With Dementia: A Randomized Controlled Feasibility Study[NCT04236557]24 participants (Actual)Interventional2022-11-01Completed
Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548]450 participants Interventional2001-03-31Completed
An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277]Phase 367 participants (Actual)Interventional2006-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change of the Agitation-Calmness Evaluation Scale (ACES) Score From Baseline to 120 Minutes After 1st Injection

Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

Interventionunits on a scale (Mean)
1. IM Olanzapine2.14
2. IM Haloperidol Pus Lorazepam2.23

The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection

The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

Interventionunits on a scale (Mean)
1. IM Olanzapine-10.2
2. IM Haloperidol Plus Lorazepam-9.9

Reviews

5 reviews available for pirenzepine and Psychomotor Agitation

ArticleYear
Continuum of care: stabilizing the acutely agitated patient.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, Sep-01, Volume: 59, Issue:17 Suppl 5

    Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Continuity of Patient Care; Cost-Be

2002
Recent developments in pharmacotherapy for the acutely psychotic patient.
    Journal of emergency nursing, 2002, Volume: 28, Issue:6 Suppl

    Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr

2002
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 10

    Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol

1999
Rationale and guidelines for the inpatient treatment of acute psychosis.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug

2000
[Drug-induced akathisia].
    Nederlands tijdschrift voor geneeskunde, 2002, Jan-19, Volume: 146, Issue:3

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Complications; D

2002

Trials

11 trials available for pirenzepine and Psychomotor Agitation

ArticleYear
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
    The American journal of emergency medicine, 2003, Volume: 21, Issue:3

    Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl

2003
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B

2003
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-

2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric

2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:1

    Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus

2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    The American journal of psychiatry, 2001, Volume: 158, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship,

2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
    Psychiatry and clinical neurosciences, 2001, Volume: 55, Issue:4

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Female; Humans; Japa

2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:4

    Topics: Adult; Affect; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Choline

2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2001,Fall, Volume: 9, Issue:4

    Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit

2001
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 26, Issue:4

    Topics: Acute Disease; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Bl

2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Archives of general psychiatry, 2002, Volume: 59, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio

2002

Other Studies

6 other studies available for pirenzepine and Psychomotor Agitation

ArticleYear
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:5

    Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H

2002
Neuroleptic malignant syndrome due to olanzapine.
    Psychopharmacology bulletin, 2001,Summer, Volume: 35, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza

2001
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.
    Pharmacopsychiatry, 2003, Volume: 36, Issue:4

    Topics: Aged; Aged, 80 and over; Benzodiazepines; Coma; Female; Humans; Hypoglycemia; Olanzapine; Pirenzepin

2003
Measuring neuroleptic-induced akathisia by three-channel actometry.
    Schizophrenia research, 1999, Nov-30, Volume: 40, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Diagnos

1999
Lethal catatonia responding to high-dose olanzapine therapy.
    Journal of psychopharmacology (Oxford, England), 2001, Volume: 15, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Catatonia; Electroconvulsive Therapy

2001
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.
    Journal of child and adolescent psychopharmacology, 2002,Spring, Volume: 12, Issue:1

    Topics: Acute Disease; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship

2002